Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Vaxart
Deal Size : Undisclosed
Deal Type : Agreement
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
Details : Under the terms of the agreement, KindredBio will provide manufacturing services for the manufacture of Vaxart 's oral vaccine candidate for COVID-19 from its state-of-the-art biological development and cGMP production facility in Burlingame, CA.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 20, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Vaxart
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : Dechra Pharmaceuticals Manufacturing
Deal Size : Undisclosed
Deal Type : Divestment
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction
Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $43.0 million
March 16, 2020
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : Dechra Pharmaceuticals Manufacturing
Deal Size : Undisclosed
Deal Type : Divestment
LOOKING FOR A SUPPLIER?